Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab

Orbit (London)

Volumn 33, Issue 6, 2014, Pages 424-427

  McElnea, Elizabeth ^a   Ní Mhéalóid, Áine ^a   Moran, Sarah ^a   Kelly, Rory ^a   Fulcher, Tim ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Ipilimumab; Myositis; Thyroid eye disease; Thyroid orbitopathy

Indexed keywords

IPILIMUMAB; METHYLPREDNISOLONE; PREDNISOLONE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; GLUCOCORTICOID; MONOCLONAL ANTIBODY; THYROXINE;

AGED; ARTICLE; CASE REPORT; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; EUTHYROIDISM; EXOPHTHALMOS; EXTRAOCULAR MUSCLE; EYE MOVEMENT; EYE REDNESS; FEMALE; FREE THYROXINE INDEX; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; PHYSICAL EXAMINATION; THYROID FUNCTION TEST; THYROID LIKE ORBITOPATHY; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; BLOOD; CHEMICALLY INDUCED; COMPLICATION; EUTHYROID SICK SYNDROME; GRAVES OPHTHALMOPATHY; SECONDARY;

AGED; ANTIBODIES, MONOCLONAL; EUTHYROID SICK SYNDROMES; EXOPHTHALMOS; FEMALE; GLUCOCORTICOIDS; GRAVES OPHTHALMOPATHY; HUMANS; MELANOMA; METHYLPREDNISOLONE; OPHTHALMOPLEGIA; THYROID FUNCTION TESTS; THYROTROPIN; THYROXINE;

EID: 84908611245     PISSN: 01676830     EISSN: 17445108     Source Type: Journal    
DOI: 10.3109/01676830.2014.949792     Document Type: Article

References (16)

1. Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumour immunotherapy. Ann Rev Immunol 2001;19:565-594.
2. Dillard T, Yedinak CG, Alumkal J, Fleseriu M. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 2010;13(1):29-38.
3. Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol 2011;164(2):303-307.
4. Blansfield JA, Beck KE, Tran K, et al. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 2005;28(6):593-598.
5. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-723.
6. Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer 2014;21(2):371-381.
7. Borodic G, Hinkle DM, Cia Y. Drug-induced graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg 2011;27(4):87-88.
8. Lecouflet M, Verschoore M, Giard C, et al. Myosite orbitaire associée à un traitement par ipilimumab. Ann Dermatol Venereol 2013;140(6-7):448-451.
9. Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010;362(8):726-738.
10. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005;23(25):6043-6053.
11. Weber J, Thompson JA, Hamid O, et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009;15(17):5591-5598.
12. Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007;13(22 Part 1):6681-6688.
13. Chistiakov DA, Turakulov RI. CTLA-4 and its role in autoimmune thyroid disease. J Mol Endocrinol 2003;31(1):21-36.
14. Vaidya B, Imrie H, Perros P, et al. Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy. Lancet 1999;354(9180):743-744.
15. Bednarczuk T, Gopinath B, Ploski R, Wall JR. Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack? Clin Endocrinol 2007;67(1):3-19.
16. Han S, Zhang S, Zhang W, et al. CTLA4 polymorphisms and ophthalmopathy in Graves' disease patients: association study and meta-analysis. Hum Immunol 2006;67(8):618-626.